Prestige Consumer Healthcare, Inc. (PBH) Securities Fraud Investigation - Levi & Korsinsky
Levi & Korsinsky, LLP has launched a securities fraud investigation into Prestige Consumer Healthcare, Inc. (NYSE: PBH) after the company's Q4 fiscal 2026 earnings and revenue fell short of expectations, leading to a sharp drop in stock price. The investigation focuses on whether Prestige Consumer Healthcare made materially false or misleading statements regarding its supply-chain remediation, particularly for its Clear Eyes product, and its earnings guidance. Shareholders who suffered losses are encouraged to contact Levi & Korsinsky for a free evaluation of their legal rights.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prestige Consumer Healthcare Inc. - PBH
Pomerantz LLP has launched an investigation into potential securities fraud and unlawful business practices by Prestige Consumer Healthcare Inc. (NYSE: PBH) and its officers. This follows a significant drop in Prestige's stock price after the company reported a 4.5% organic revenue decrease for fiscal year 2026 and revealed delayed shipments and production shutdowns for its Clear Eyes product line. Investors who suffered losses are encouraged to contact the law firm.
PBH Investor Alert: Levi & Korsinsky Investigates Prestige Consumer Healthcare (PBH) for Potential Securities Fraud
Levi & Korsinsky is investigating Prestige Consumer Healthcare (PBH) for potential securities fraud following its Q4 FY 2026 earnings miss. The investigation centers on whether the company's officers and directors made misleading statements regarding financial projections, specifically after revenue and EPS fell short of previous guidance. Shareholders who incurred losses are encouraged to contact the law firm to discuss their legal options.
PBH Investor Alert: Levi & Korsinsky Investigates Prestige Consumer Healthcare (PBH) for Potential Securities Fraud
Levi & Korsinsky is investigating Prestige Consumer Healthcare (PBH) for potential securities fraud following a Q4 FY 2026 earnings miss. The investigation focuses on whether the company's officers and directors made materially false or misleading statements regarding financial projections, especially revenue and adjusted diluted EPS, which fell short of prior guidance. Shareholders who suffered losses are encouraged to contact Levi & Korsinsky to discuss their legal options.
INVESTOR ALERT: Investigation of Prestige Consumer Healthcare Inc. (PBH) announced by Holzer & Holzer, LLC
Holzer & Holzer, LLC has initiated an investigation into Prestige Consumer Healthcare Inc. (NYSE: PBH) following a drop in its stock price. This comes after the company reported a 5% decrease in fourth-quarter revenues compared to the prior year, with the CEO citing delayed shipments and production shutdowns as contributing factors. The firm is encouraging investors who experienced losses to contact them to discuss their legal rights.
Prestige Consumer Healthcare (PBH) Valuation After Missed Q4 Targets And Delayed LaCorium Deal Disclosure
Prestige Consumer Healthcare (PBH) has seen its stock drop significantly after missing Q4 FY2026 financial targets and belatedly disclosing a US$150 million acquisition deal, leading to a shareholder investigation. Despite trading below fair value estimates, concerns remain about execution risks, future growth, and reliance on mature brands. The article suggests reviewing the numbers to form an independent view but notes the company's strong free cash flow provides financial flexibility.
Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives Average Recommendation of "Hold" from Analysts
Prestige Consumer Healthcare Inc. (NYSE:PBH) has an average "Hold" recommendation from analysts, with a consensus 12-month price target of $70.75. The company recently reported fiscal Q4 EPS and revenue below Wall Street expectations, leading to downgrades, reduced price targets from some firms, and securities-fraud investigations. Shares are trading significantly below their 52-week high, reflecting the negative sentiment surrounding recent financial performance.
Prestige Consumer Healthcare: Better Valuation, But Too Much Uncertainty To Buy
Prestige Consumer Healthcare (PBH) ended FY26 with an earnings miss and is projected to have a slow start to FY27. While acquisitions will boost revenue, they will also increase the company's debt. Despite a more attractive valuation, the author expresses too much uncertainty to recommend buying the stock at this time.
Bessemer Group Inc. Acquires 32,331 Shares of Prestige Consumer Healthcare Inc. $PBH
Bessemer Group Inc. has increased its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 11.6%, acquiring an additional 32,331 shares to bring its total holdings to 309,931 shares valued at approximately $19.1 million. This increase comes as Prestige Consumer Healthcare recently missed its Q4 earnings and revenue expectations, reporting EPS of $1.23 against a $1.39 consensus and revenue of $281.6 million against $293.6 million expected, leading to a more cautious analyst sentiment with reduced price targets and a downgrade from Oppenheimer. Despite this, institutional investors collectively own 99.95% of the stock.
How InvestingPro’s Fair Value spotted Prestige Healthcare’s 46% drop
This article details how InvestingPro's Fair Value analysis accurately predicted a 46% drop in Prestige Consumer Healthcare (NYSE:PBH) stock. The tool identified the stock as overvalued by over 40% in February 2025, leading to a significant decline by May 2026. The case study highlights the importance of fair value analysis in identifying overvalued stocks and protecting portfolios from substantial losses.
Securities Fraud Investigation Into Prestige Consumer Healthcare (PBH) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
The Law Offices of Frank R. Cruz announced a securities fraud investigation into Prestige Consumer Healthcare (PBH) following a significant drop in its stock price. This investigation comes after the company reported a revenue decrease of 4.5% organically for fiscal year 2026 and revealed production shutdowns and delayed shipments for Clear Eyes sales, leading to an 11.35% share price decline on May 14, 2026. Shareholders who lost money are encouraged to contact the law firm to inquire about potentially pursuing a claim.
Prestige Consumer Healthcare, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Prestige Consumer Healthcare (PBH)
Levi & Korsinsky, LLP has initiated an investigation into Prestige Consumer Healthcare (PBH) concerning statements made by executives that allegedly overstated the company's financial trajectory. The investigation focuses on missed Q4 FY 2026 projections for adjusted gross margin, free cash flow, and adjusted diluted EPS, as well as the undisclosed $150 million acquisition of LaCorium prior to the Q4 results. Shareholders who suffered losses due to the significant decline in PBH shares following the Q4 disclosure are encouraged to contact the firm.
Prestige Consumer Healthcare Inc. (NYSE:PBH) Q4 2026 Earnings Call Transcript
Prestige Consumer Healthcare Inc. (NYSE:PBH) reported challenging Q4 2026 results with a 4% full-year revenue decline, primarily due to Eye Care supply constraints and international shipping disruptions. Despite this, the company expects to return to organic growth in fiscal 2027 and announced two significant acquisitions: Breathe Right and LaCorium Health, aiming to strengthen its portfolio and accelerate growth. Prestige Consumer Healthcare projects revenues of $1.1 billion to $1.12 billion for fiscal 2027, with organic growth of 1% to 3%, and a long-term goal of approximately 10% sales CAGR through fiscal 2029, driven by strategic acquisitions and Eye Care recovery.
Prestige Consumer Healthcare (PBH) Margin Slippage Tests Bullish Valuation Narratives In FY 2026
Prestige Consumer Healthcare (PBH) closed FY 2026 with a reported revenue of US$281.6 million and EPS of US$1.14 for the fourth quarter, and trailing twelve-month revenue of US$1.09 billion and EPS of US$3.93. Despite bullish narratives citing supply chain fixes and e-commerce growth, the company's net income and net profit margin have declined from the previous year, now sitting at US$190.3 million and 17.5% respectively. This margin slippage, coupled with high debt and a P/E ratio below industry averages, challenges the optimistic long-term growth and valuation views, necessitating a closer look at how various initiatives translate into actual profit.
Prestige Consumer Healthcare forecasts $1.1B-$1.12B fiscal 2027 revenue with Clear Eyes growth weighted to the back half
Prestige Consumer Healthcare has forecast its fiscal 2027 revenue to be between $1.1 billion and $1.12 billion. The company anticipates the growth of its Clear Eyes product line to be more significant in the latter half of the fiscal year.
Prestige Consumer Healthcare Inc. FY 2026: Revenue $1.09B, EPS $3.91— 10-K Summary
Prestige Consumer Healthcare Inc. reported its fiscal 2026 results, showing declines in revenue, net income, and diluted EPS compared to the prior year. The decreases were primarily attributed to lower North American OTC sales, supply constraints, and retailer ordering shifts towards e-commerce. Despite these challenges, the company completed the Pillar5 acquisition and has a pending acquisition of the Breathe Right® portfolio.
Step Back in Clear Eyes Recovery and Macro Challenges Weigh on Prestige in Near Term
The article discusses Prestige Consumer Healthcare's strategy, focusing on growth through product innovation, increased household penetration, and e-commerce expansion, particularly in niche over-the-counter markets. Weak year-end results and soft guidance have led to a stock value downgrade. The company aims to expand indications for existing brands and target underpenetrated categories.
PBH Q4 Earnings & Revenues Miss Estimates, Margins Down
Prestige Consumer Healthcare Inc. (PBH) reported disappointing fourth-quarter and fiscal 2026 results, with both earnings and revenues falling short of estimates. The decline was attributed to lower sales in the Eye & Ear Care category due to supply limitations for Clear Eyes and shipping disruptions in the Middle East. Despite a strong performance in its Gastrointestinal portfolio, the company's gross and operating margins contracted, and it provided a conservative outlook for fiscal 2027.
Prestige Consumer Healthcare Inc. Reports Fiscal 2026 Results, Announces Acquisition Of LaCorium Health >PBH
Prestige Consumer Healthcare Inc. reported its fiscal 2026 results and announced the acquisition of LaCorium Health. The financial details and strategic implications of this acquisition will be of interest to investors and market observers. This move is expected to expand Prestige's presence in the consumer healthcare market.
Prestige Consumer Healthcare reports fiscal 2026 results, plans acquisition
Prestige Consumer Healthcare Inc. (NYSE:PBH) reported a decrease in revenues for fiscal year 2026, totaling $1,088.7 million, down 4.3% from the previous year, primarily due to production and shipping disruptions. Despite the decline, the company announced the acquisition of Australian skincare company LaCorium Health for $150 million and projected organic revenue growth for fiscal 2027. InvestingPro analysis indicates the stock appears undervalued with a P/E ratio of 13.7 and an 11% free cash flow yield.
Prestige Consumer Healthcare: Fiscal Q4 Earnings Snapshot
Prestige Consumer Healthcare (PBH) reported fiscal fourth-quarter net income of $53.9 million, or $1.13 per share, with adjusted earnings of $1.23 per share. These results, along with revenue of $281.6 million, fell short of Wall Street expectations. For the full year, the company had a profit of $190.3 million on $1.09 billion in revenue and forecasts full-year revenue between $1.1 billion and $1.12 billion.
Prestige to buy $150M Australian skin-care maker LaCorium
Prestige Consumer Healthcare (PBH) reported fiscal 2026 revenues of $1,088.7 million and diluted EPS of $3.91, both showing a decline year-over-year, while free cash flow increased to $246.4 million. The company announced the acquisition of LaCorium Health, an Australian therapeutic skin-care maker, for approximately $150 million in cash. Looking ahead to fiscal 2027, Prestige projects revenues of $1.10–$1.121 billion, organic growth of 1–3%, and adjusted EPS of $4.42–$4.51.
Prestige Consumer Healthcare: Fiscal Q4 Earnings Snapshot
Prestige Consumer Healthcare Inc. reported fiscal fourth-quarter net income of $53.9 million, or $1.13 per share, with adjusted earnings of $1.23 per share. These results, along with revenue of $281.6 million, fell short of Wall Street expectations. The company anticipates full-year revenue for the upcoming fiscal year to be between $1.1 billion and $1.12 billion.
Prestige Consumer Healthcare Inc. Reports Fiscal 2026 Results, Announces Acquisition of LaCorium Health
Prestige Consumer Healthcare Inc. reported decreased revenues for fiscal year 2026 at $1,088.7 million, down 4.3% from the prior year, attributed primarily to challenges with Clear Eyes® supply. Despite this, the company generated $246.4 million in free cash flow and announced the acquisition of LaCorium Health for approximately $150 million, a move expected to strengthen its dermatological portfolio. For fiscal year 2027, Prestige anticipates organic revenue growth of 1% to 3% and adjusted diluted EPS in the range of $4.42 to $4.51, reflecting a strategic expansion and expected recovery in eye care capacity.
Prestige Consumer Healthcare earnings on deck amid M&A push
Prestige Consumer Healthcare (NYSE:PBH) is scheduled to report its fiscal fourth-quarter results, with analysts expecting strong sequential growth in EPS and revenue. Investors are focusing on the company's ability to sustain this growth, integrate a recent major acquisition, and address regulatory pressures and category-specific headwinds. The M&A-driven expansion is anticipated to be a key factor in boosting investor confidence.
Insider Sell: Jeffrey Zerillo Sells Shares of Prestige Consumer Healthcare Inc (PBH)
Jeffrey Zerillo, Senior Vice President of Operations at a Prestige Consumer Healthcare Inc (PBH) subsidiary, sold 351 shares of the company on May 11, 2026. This transaction increased his total holdings to 41,810 shares. The stock is currently trading at $52.28, suggesting it is modestly undervalued compared to its GF Value of $67.96.
Prestige Consumer (PBH) SVP sells 351 shares at $52.28
Prestige Consumer Healthcare Inc.'s Senior VP Operations, Jeffrey Zerillo, sold 351 shares of common stock on the open market at $52.28 per share on May 11, 2026. Following this transaction, Zerillo directly holds 41,810 shares of the company. The sale was executed pursuant to a Rule 10b5-1 trading plan.
Prestige consumer healthcare senior VP sells $18,350 in shares By Investing.com
Jeffrey Zerillo, Senior VP Operations at Prestige Consumer Healthcare Inc. (NASDAQ:PBH), sold 351 shares of the company's common stock for a total of $18,350 on May 11, 2026. This transaction occurred as PBH stock was trading near its 52-week low. The company also recently announced a significant acquisition of the Breathe Right brand and other related brands from Foundation Consumer Healthcare for $1.045 billion.
Insider Sell: Jeffrey Zerillo Sells Shares of Prestige Consumer Healthcare Inc (PBH)
Jeffrey Zerillo, Senior Vice President of Operations at a Prestige Consumer Healthcare Inc subsidiary, recently sold 305 shares of PBH, reducing his holdings to 42,161 shares. This transaction is part of a pattern over the past year with six insider sells and no buys. Prestige Consumer Healthcare, trading at $54.36, appears modestly undervalued with a price-to-GF-Value ratio of 0.8, based on GuruFocus's intrinsic value estimate.
Prestige Consumer (NYSE: PBH) CFO reports routine tax-withholding share disposition
Prestige Consumer Healthcare Inc. (NYSE: PBH) CFO & COO Christine Sacco reported a routine tax-related disposition of 991 common shares on May 7, 2026, at a price of $54.59 per share to cover tax obligations. This non-market transaction resulted in her directly owning 71,636 shares of the company's common stock. The filing, a Form 4, indicates a tax-withholding disposition, not an open-market sale.
Prestige Consumer (PBH) EVP reports 487-share tax withholding on Form 4
Prestige Consumer Healthcare EVP Mekhail Adel reported a tax-related disposition of 487 shares of common stock on May 7, 2026, at a price of $54.59 per share, to cover tax obligations. Following this transaction, Adel directly holds 25,703 shares of PBH. This event, filed as a Form 4, is a routine administrative tax withholding and not a discretionary open-market sale.
Prestige Consumer (PBH) SVP Zerillo sells shares, withholds stock for tax
Jeffrey Zerillo, Senior VP of Operations at Prestige Consumer Healthcare (PBH), recently sold 305 shares of common stock for $54.36 per share. Additionally, 351 shares were withheld at $54.59 per share to cover tax obligations, a non-market transaction. After these actions, Zerillo directly holds 42,161 shares, indicating the sale represents a small portion of his total stake.
Prestige Consumer Healthcare Drops 6.0% Amid Sector-Wide Selling
Prestige Consumer Healthcare Inc. (PBH) saw a 6.0% drop in its stock price on Monday to $49.41, part of a broad selloff affecting specialty drug makers. The decline was mirrored by peers NKTR and TARS, and comes amidst weakening analyst sentiment with one recent price target cut and no raises. Investors are advised to monitor sector performance and further analyst commentary.
Fidelity files Rule 144 to offer 351 PBH shares (NYSE: PBH)
Fidelity Brokerage Services LLC has filed a Rule 144 notice to offer 351 shares of Prestige Consumer Healthcare Inc. (NYSE: PBH) common stock. These shares are related to Restricted Stock Vesting on May 7, 2026. The filing also notes previous sales by Jeffrey Zerillo totaling 2,858 shares in February and May 2026.
Prestige Consumer Healthcare (PBH) Q4 2026 Preview: EPS Est. $1.39, Reports May 14
Prestige Consumer Healthcare (PBH) is expected to report its Q4 fiscal 2026 earnings on May 14, with analysts forecasting EPS of $1.39 on revenue of $293.7 million. While this represents a 5.3% increase in EPS year-over-year, revenue is projected to decline by 0.9%. Investors will be closely watching for details on net margin, product category performance, and fiscal 2027 guidance to assess the sustainability of profit growth amid revenue headwinds.
Prestige consumer healthcare senior VP sells $66,372 in stock By Investing.com
Jeffrey Zerillo, Senior VP of Operations at Prestige Consumer Healthcare Inc. (NASDAQ:PBH), sold 1,207 shares of company stock for $66,372 on May 5, 2026. An additional 307 shares were disposed of to cover tax withholding obligations. These transactions occurred while PBH stock was near its 52-week low, and prior to the company's announcement of acquiring the Breathe Right brand for $1.045 billion.
Insider Sell: Jeffrey Zerillo Sells Shares of Prestige Consumer Healthcare Inc (PBH)
Jeffrey Zerillo, Senior Vice President of Operations at a Prestige Consumer Healthcare Inc subsidiary, sold 1,207 shares of PBH on May 5, 2026, bringing his total ownership to 42,820 shares. This transaction is part of a trend of insider selling at the company, with five insider sells and no buys in the past year. Prestige Consumer Healthcare Inc is currently valued at $54.99 per share, with a price-to-GF-Value ratio of 0.81, suggesting it is modestly undervalued.
Prestige Consumer (PBH) CFO uses 1,267 shares to cover tax liability
Prestige Consumer Healthcare's CFO & COO, Christine Sacco, reported a tax-related share disposition. On May 5, 2026, 1,267 shares of common stock were withheld at $55.75 per share to cover tax obligations. Following this transaction, she directly owned 72,627 shares of the company's common stock.
Prestige Consumer SVP (NYSE: PBH) sells 1,207 common shares
Jeffrey Zerillo, Senior VP Operations at Prestige Consumer Healthcare (NYSE: PBH), reported an open-market sale of 1,207 shares at $54.99 each. Additionally, 307 shares were disposed of to cover tax withholding obligations at $55.75 per share. Following these transactions, Zerillo's direct holdings in the company are 42,820 shares.
Prestige Consumer (NYSE: PBH) CEO has 2,197 shares withheld to cover tax
Prestige Consumer Healthcare Inc.'s CEO, Ronald M. Lombardi, had 2,197 shares of common stock withheld at $55.75 per share to satisfy a tax liability. This transaction was a tax-withholding disposition, not an open-market sale. Following this event, Lombardi directly holds 376,008 shares of the company's common stock.
305 shares proposed for sale; Zerillo reported recent sales (PBH)
Prestige Consumer Healthcare Inc. (PBH) has filed a Form 144 indicating a proposed sale of 305 shares linked to restricted stock vesting on May 5, 2026. The filing also details multiple recent sales by Jeffrey A. Zerillo, totaling 2,553 shares across February and May 2026. This report provides an overview of the proposed sale, recent insider transactions, and related financial figures.
Prestige consumer healthcare senior VP sells $66,372 in stock
Prestige Consumer Healthcare Inc.'s Senior VP of Operations, Jeffrey Zerillo, sold 1,207 shares of common stock for $66,372 and disposed of an additional 307 shares worth $17,115 to cover tax withholding obligations. The stock (PBH) is currently trading near its 52-week low and is considered undervalued by InvestingPro analysts, despite the insider sale. The company recently announced a significant acquisition of the Breathe Right brand and related brands for $1.045 billion, aiming to expand its operations.
Oppenheimer Adjusts Price Target on Prestige Consumer Healthcare to $65 From $77, Maintains Outperform Rating
Oppenheimer has lowered its price target for Prestige Consumer Healthcare (PBH) from $77 to $65, while reiterating an Outperform rating. This adjustment reflects a revised valuation outlook for the company but maintains a positive long-term view on its stock.
Prestige Consumer (NYSE: PBH) CEO gets stock awards and tax withholding
Prestige Consumer Healthcare Inc.'s CEO, Ronald M. Lombardi, received 19,662 shares from vested performance stock units and a new grant of 31,468 Restricted Stock Units. To cover tax obligations, 16,789 shares were disposed of through a tax-withholding mechanism at $55.31 per share. Following these transactions, Lombardi directly holds 358,543 shares of common stock, with new RSUs vesting in equal installments over the next three years.
Prestige Consumer (NYSE: PBH) CFO gets stock awards, tax shares withheld
Prestige Consumer Healthcare Inc.'s CFO & COO, Christine Sacco, received stock awards totaling 11,976 shares from vested performance stock units and a new grant of 7,008 restricted shares. To cover tax obligations, 3,434 shares were withheld at $55.31 each. Following these transactions, Sacco directly holds 61,918 shares of Prestige Consumer Healthcare common stock.
Prestige Consumer (NYSE: PBH) executive reports new stock units and tax withholding
Prestige Consumer Healthcare executive William P'Pool received equity compensation awards, including the settlement of 4,187 performance stock units and a new grant of 3,675 Restricted Stock Units. To cover tax obligations, 1,888 shares were withheld at $55.31 per share. After these transactions, P'Pool directly holds 25,850 common shares, with an additional 100 shares held indirectly in a charitable fund.
Prestige Consumer Healthcare (PBH) SVP logs stock grants, tax withholding and sale
Prestige Consumer Healthcare's Senior VP of Operations, Jeffrey Zerillo, engaged in routine equity compensation activities, including receiving stock awards and a minor open-market share sale. He was granted a total of 5,307 common shares and disposed of 1,243 shares for tax obligations, while also selling 346 shares at $55.32 each. After these transactions, Zerillo directly holds 44,334 shares of Prestige Consumer Healthcare stock.
Prestige Consumer (NYSE: PBH) EVP receives stock awards, tax shares withheld
Adel Mekhail, EVP of Marketing & Sales at Prestige Consumer Healthcare (NYSE: PBH), reported equity compensation activities including the acquisition of 4,014 shares from vested performance stock units and 3,505 restricted stock shares. The company withheld 1,695 shares at $55.31 each to cover tax obligations. Following these transactions, Mekhail directly owns 23,871 common shares, with the restricted stock vesting in three equal installments through May 2029.
Prestige Consumer Healthcare (NYSE:PBH) - Stock Analysis
This report provides a comprehensive stock analysis of Prestige Consumer Healthcare (NYSE:PBH), highlighting its valuation, future growth prospects, past performance, financial health, and dividend policy. The company is currently trading at a discount to its estimated fair value, with analysts forecasting moderate earnings growth, although it faces challenges with a high debt level. Recent news includes share repurchase programs, upcoming earnings reports, and an acquisition that expands its product portfolio, alongside consistent insider selling.
Prestige Consumer (PBH) officer logs 599-share tax withholding and 22,175-share holding
Prestige Consumer Healthcare Inc. officer William P’Pool reported a routine disposition of 599 shares at $55.09 each for tax withholding purposes on May 2, 2026. Following this transaction, P'Pool directly holds 22,175 shares. Additionally, 100 shares are held indirectly in the P'Pool Family Giving Fund via Fidelity Charitable, indicating a charitable holding rather than personal trading.
